Alabama lawmakers passed a bill on Thursday that would criminalize gender-affirming healthcare for transgender youth, with a threat of 10 years in prison for medical providers.

For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]

Myovant announced that the company’s Phase III HERO trial relugolix met the study’s primary endpoint and six key secondary endpoints in advanced prostate cancer.

The U.S. Food and Drug Administration declined to approve Lipocine Inc.’s oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer’s shares down 34 percent.

Pfizer Inc. and Astellas Pharma Inc. announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).

The U.S. Food and Drug Administration approved Antares Pharma Inc.’s injectable drug Xyosted to treat low testosterone levels in men nearly a year after being rejected.

A federal jury in Chicago found AbbVie Inc. fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

Lipocine Inc. said its oral testosterone replacement product did not get the approval in the United States, sending the drugmaker’s shares down 52 percent in premarket trading.